Current status of Rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 4, 2009, Pages 322-330

  Dong, Ming ^a   Yan, Bryan P ^a   Yu, Chuek Man ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atheroscleorosis; Coronary spasm; Inhibitor; Rho kinase (ROCK)

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ATORVASTATIN; EZETIMIBE; FASUDIL; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHO KINASE; SIMVASTATIN; TROPONIN; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANGINA PECTORIS; ATHEROSCLEROSIS; BRAIN VASOSPASM; CARDIOVASCULAR EFFECT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY SPASM; DRUG INHIBITION; DRUG STRUCTURE; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; CORONARY ARTERY DISEASE; CORONARY VASOSPASM; HUMANS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 74049110911     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789541891     Document Type: Review

References (116)

1. Narumiya, S.; Ishizaki, T.; Watanabe, N. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett., 1997, 410, 68.
2. Takai, Y.; Sasaki, T.; Tanaka, K.; Nakanishi, H. Rho as a regulator of the cytoskeleton. Trends Biochem. Sci., 1995, 20, 227.
3. Kaibuchi, K.; Kuroda, S.; Amano, M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu. Rev. Biochem., 1999, 68, 459.
4. Somlyo, A.P.; Somlyo, A.V. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and nonmuscle myosin II. J. Physiol., 2000, 522(Pt 2), 177.
5. Shimokawa, H.; Takeshita, A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1767.
6. Sauzeau, V.; Rolli-Derkinderen, M.; Marionneau, C.; Loirand, G.; Pacaud, P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J. Biol. Chem., 2003, 278, 9472.
7. Nohria, A.; Grunert, M.E.; Rikitake, Y.; Noma, K.; Prsic, A.; Ganz, P; Liao, J.K.; Creager, M.A. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ. Res., 2006, 99, 1426.
8. Noma, K.; Oyama, N.; Liao, J.K. Physiological role of ROCKs in the cardiovascular system. Am. J. Physiol. Cell Physiol., 2006, 290, C661-C668.
9. B̈ussemaker, E.; Pistrosch, F.; F̈orster, S.; Herbrig, K.; Gross, P.; Passauer, J.; Brandes, R.P. Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H541-H547.
10. Serrano, C.V., Jr.; Ramires, J.A.; Venturinelli, M.; Arie, S.; D'Amico, E.; Zweier, J.L.; Pileggi, F.; da Luz, P.L. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J. Am. Coll. Cardiol., 1997, 29, 1276.
11. Tanaka, H.; Sukhova, G.K.; Swanson, S.J.; Clinton, S.K.; Ganz, P.; Cybulsky, M.I.; Libby, P. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation, 1993, 88, 1788.
12. Noma, K.; Rikitake, Y.; Oyama, N.; Yan, G.; Alcaide, P.; Liu, P.Y.; Wang, H.; Ahl, D.; Sawada, N.; Okamoto, R.; Hiroi, Y.; Shimizu, K.; Luscinskas, F.W.; Sun, J.; Liao, J.K. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J. Clin. Invest., 2008, 118(5), 1632.
13. Nohria, A.; Prsic, A.; Liu, P.Y.; Okamoto, R.; Creager, M.A.; S elwyn, A, Liao, J.K.; Ganz, P. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis, 2008. [Epub ahead of print].
14. Rawlings, R.; Nohria, A.; Liu, P.Y.; Donnelly, J.; Creager, M.A.; Ganz, P.; Selwyn, A.; Liao, J.K. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am. J. Cardiol., 2009, 103(4), 437.
15. Smilde, T.J.; van Wissen, S.; Wollersheim, H.; Trip, M.D.; Kastelein, J.J.; Stalenhoef, A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, doubleblind trial. Lancet, 2001, 357, 577.
16. Crouse, J.R., 3rd.; Raichlen, J.S.; Riley, W.A.; Evans, G.W.; Palmer, M.K.; O'Leary, D.H.; Grobbee, D.E.; Bots, M.L. METEOR Study Group. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA, 2007, 297, 1344.
17. Ishizaki, T.; Maekawa, M.; Fujisawa, K.; Okawa, K.; Iwamatsu, A.; Fujita, A.; Watanabe, N.; Saito, Y.; Kakizuka, A.; Morii, N.; Narumiya, S. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J., 1996, 15, 1885.
18. Leung, T.; Chen, X.Q.; Manser, E.; Lim, L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell Biol., 1996, 16, 5313.
19. Leung, T.; Manser, E.; Tan, L., Lim, L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J. Biol. Chem., 1995, 270, 29051.
20. Matsui, T.; Amano, M.; Yamamoto, T.; Chihara, K.; Nakafuku, M.; Ito, M.; Nakano, T.; Okawa, K.; Iwamatsu, A.; Kaibuchi, K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J., 1996, 15, 2208.
21. Nakagawa, O.; Fujisawa, K.; Ishizaki, T.; Saito, Y.; Nakao, K.; Narumiya, S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett., 1996, 392(2), 189.
22. Chevrier, V.; Piel, M.; Collomb, N.; Saoudi, Y.; Frank, R.; Paintrand, M.; Narumiya, S.; Bornens, M.; Job, D. The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J. Cell Biol., 2002, 157, 807.
23. Kosako, H.; Goto, H.; Yanagida, M.; Matsuzawa, K.; Fujita, M.; Tomono, Y.; Okigaki, T.; Odai, H.; Kaibuchi, K.; Inagaki, M. Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments. Oncogene, 1999, 18(17), 2783.
24. Kawabata, S.; Usukura, J.; Morone, N.; Ito, M.; Iwamatsu, A.; Kaibuchi, K.; Amano, M. Interaction of Rho-kinase with myosin II at stress fibres. Genes Cells, 2004, 9(7), 653.
25. Sin, W. C.; Chen, X. Q.; Leung, T.; Lim, L. RhoA-binding kinase alpha translocation is facilitated by the collapse of the vimentin intermediate filament network. Mol. Cell Biol., 1998, 18(11), 6325.
26. Wibberley, A.; Chen, Z.; Hu, E.; Hieble, J.P.; Westfall, T.D. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br. J. Pharmacol., 2003, 138(5), 757.
27. Noma, K.; Goto, C.; Nishioka, K.; Jitsuiki, D.; Umemura, T.; Ueda, K.; Kimura, M.; Nakagawa, K.; Oshima, T.; Chayama, K.; Yoshizumi, M.; Liao, J.K.; Higashi, Y. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J. Am. Coll. Cardiol., 2007, 49(6), 698.
28. Wei. L.; Roberts, W.; Wang, L.; Yamada, M.; Zhang, S.; Zhao, Z.; Rivkees, S.A.; Schwartz, R.J.; Imanaka-Yoshida, K. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development, 2001, 128, 2953.
29. Hiroki, J.; Fukumoto, Y.; Shimokawa, H.; Hirooka, Y.; Takeshita, A. Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report. J. Cardiol., 2004, 44(4), 161.
30. Hiroki, J.; Shimokawa, H.; Mukai, Y.; Ichiki, T.; Takeshita, A. Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2005, 326(1), 154.
31. Hiroki, J., Shimokawa, H., Mukai, Y., Ichiki, T., Takeshita, A. Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2005, 326(1), 154.
32. Shimizu, Y.; Thumkeo, D.; Keel, J.; Ishizaki, T.; Oshima, H.; Oshima, M.; Noda, Y.; Matsumura, F.; Taketo, M.M.; Narumiya S. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J. Cell Biol., 2005, 168, 941.
33. Thumkeo, D.; Keel, J.; Ishizaki, T.; Hirose, M.; Nonomura, K.; Oshima, H.; Oshima, M.; Taketo, M.M.; Narumiya, S. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell Biol., 2003, 23, 5043.
34. Rikitake, Y.; Oyama, N.; Wang, C.Y.; Noma, K.; Satoh, M.; Kim, H.H.; Liao, J.K. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/2 haploinsufficient mice. Circulation, 2005, 112, 2959.
35. Thumkeo, D.; Shimizu, Y.; Sakamoto, S.; Yamada, S.; Narumiya, S. ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells, 2005, 10, 825.
36. Wang, Y.; Zheng, X.R.; Riddick, N.; Bryden, M.; Baur, W.; Zhang, X.; Surks, H.K. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ. Res., 2009, 104(4), 531.
37. Maekawa, M.; Ishizaki, T.; Boku, S.; Watanabe, N.; Fujita, A.; Iwamatsu, A.; Obinata, T.; Ohashi, K.; Mizuno, K.; Narumiya, S. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIMkinase. Science, 1999, 285, 895.
38. Kawano, Y.; Fukata, Y.; Oshiro, N.; Amano, M.; Nakamura, T.; Ito, M.; Matsumura, F.; Inagaki, M.; Kaibuchi, K. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J. Cell Biol., 1999, 147, 1023.
39. Feng, J.; Ito, M.; Ichikawa, K.; Isaka, N.; Nishikawa, M.; Hartshorne, D.J.; Nakano, T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J. Biol. Chem., 1999, 274, 37385.
40. Velasco, G.; Armstrong, C.; Morrice, N.; Frame, S.; Cohen, P. Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin. FEBS Lett., 2002, 527, 101.
41. Somlyo, A.P.; Somlyo, A.V. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and nonmuscle myosin II. J. Physiol., 2000, 522(2), 177.
42. Amano, M.; Ito, M.; Kimura, K.; Fukata, Y.; Chihara, K.; Nakano, T.; Matsuura, Y.; Kaibuchi, K.. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol Chem., 1996, 271(34), 20246.
43. Iizuka, K.; Yoshii, A.; Samizo, K.; Tsukagoshi, H.; Ishizuka, T.; Dobashi, K.; Nakazawa, T.; Mori, M. A major role for the rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea. Br. J. Pharmacol., 1999, 128(4), 925.
44. Swärd, K.; Mita, M.; Wilson, D.P.; Deng, J.T.; Susnjar, M.; Walsh, M.P. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr. Hypertens. Rep., 2003, 5(1), 66.
45. Fukata, Y.; Amano, M.; Kaibuchi, K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of nonmuscle cells. Trends Pharmacol. Sci., 2001, 22(1), 32.
46. Matsui, T.; Maeda, M.; Doi, Y.; Yonemura, S.; Amano, M.; Kaibuchi, K.; Tsukita, S.; Tsukita, S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell Biol., 1998, 140, 647.
47. Fukata, Y.; Oshiro, N.; Kinoshita, N.; Kawano, Y.; Matsuoka, Y.; Bennett, V.; Matsuura, Y.; Kaibuchi, K. Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J. Cell Biol., 1999, 145, 347.
48. Kimura, K.; Ito, M.; Amano, M.; Chihara, K.; Fukata, Y.; Nakafuku, M.; Yamamori, B.; Feng, J.; Nakano, T.; Okawa, K.; Iwamatsu, A.; Kaibuchi, K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science, 1996, 273, 245.
49. Vahebi, S.; Kobayashi, T.; Warren, C.M.; de Tombe, P.P.; Solaro R.J. Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ. Res., 2005, 96, 740.
50. Sato. M.; Tani, E.; Fujikawa, H.; Kaibuchi, K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ. Res., 2000, 87, 195.
51. Sawada, N.; Tani, E.; Fujikawa, H.; Kaibuchi, K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation, 2000, 101, 2030.
52. Mallat, Z.; Gojova, A.; Sauzeau, V.; Brun, V.; Silvestre, J.S.; Esposito, B.; Merval, R.; Groux, H.; Loirand, G.; Tedgui, A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res., 2003, 93, 884.
53. Masumoto, A.; Hirooka, Y.; Shimokawa, H.; Hironaga, K.; Setoguchi, S.; Takeshita, A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension, 2001, 38, 1307.
54. Fukumoto, Y.; Matoba, T.; Ito, A.; Tanaka, H.; Kishi, T.; Hayashidani, S.; Abe, K.; Takeshita, A.; Shimokawa, H. Acute vasodilator effects of a Rhokinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart, 2005, 91, 391.
55. Masumoto, A.; Mohri, M.; Shimokawa, H.; Urakami, L.; Usui, M.; Takeshita, A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation, 2002, 105, 1545.
56. Shimokawa, H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol., 2002, 39, 319.
57. Shibuya, M.; Hirai, S.; Seto, M.; Satoh; S.; Ohtomo, E.; Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci., 2005, 238, 31.
58. Kishi, T.; Hirooka, Y.; Masumoto, A.; Ito, K.; Kimura, Y.; Inokuchi, K.; Tagawa, T.; Shimokawa, H.; Takeshita, A.; Sunagawa, K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation, 2005, 111, 2741.
59. Shibuya, M.; Suzuki, Y.; Sugita, K.; Saito, I.; Sasaki, T.; Takakura, K.; Okamoto, S.; Kikuchi, H.; Takemae, T.; Hidaka, H. Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage. Acta Neurochir, (Wien.,), 1990, 107, 11.
60. Shibuya, M.; Suzuki, Y.; Sugita, K.; Saito, I.; Sasaki, T.; Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J. Neurosurg., 1992, 76, 571.
61. Laufs, U.; La Fata, V.; Plutzky, J. Liao, J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998, 97, 1129.
62. Laufs, U.; Liao, J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem., 1998, 273, 24266.
63. Wolfrum, S.; Dendorfer, A.; Rikitake, Y.; Stalker, T.J.; Gong, Y.; Scalia, R.; Dominiak, P.; Liao, J.K. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1842.
64. Takemoto, M.; Sun, J.; Hiroki, J. Shimokawa, H.; Liao, J.K. Rho-kinase mediates hypoxiainduced downregulation of endothelial nitric oxide synthase. Circulation, 2002, 106, 57.
65. Laufs, U.; Endres, M.; Stagliano, N.; Amin-Hanjani, S.; Chui, D.S.; Yang, S.X.; Simoncini, T.; Yamada, M.; Rabkin, E.; Allen, P.G.; Huang, P.L.; Böhm, M.; Schoen, F.J.; Moskowitz, M.A.; Liao, J.K. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest., 2000, 106, 15.
66. Laufs, U.; Fata, V.L.; Liao, J.K. Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem., 1997, 272, 31725.
67. Rikitake, Y.; Kim, H.H.; Huang, Z.; Seto, M.; Yano, K.; Asano, T.; Moskowitz, M.A.; Liao, J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke, 2005, 36, 2251.
68. Amano, M.; Fukata, Y.; Kaibuchi, K. Regulation and functions of Rho-associated kinase. Exp. Cell Res., 2000, 261, 44.
69. Narumiya, S. Cellular functions & pharmacological manipulations of the small GTPase Rho & Rho effectors. Nippon Yakurigaku Zasshi, 1999, 114(Suppl. 1), 1.
70. Narumiya, S. The small GTPase Rho: Cellular functions and signal transduction. J. Biochem., 1996, 120, 215.
71. Chihara, K.; Amano, M.; Nakamura, N.; Yano, T.; Shibata, M.; Tokui, T.; Ichikawa, H.; Ikebe, R.; Ikebe, M.; Kaibuchi, K. Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. J. Biol. Chem., 1997, 272(40): 25121.
72. Essler, M.; Retzer, M.; Bauer, M.; Heemskerk, J.W.; Aepfelbacher, M.; Siess, W. Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J. Biol. Chem., 1999, 274, 30361.
73. Essig, M.; Nguyen, G.; Prie, D.; Escoubet, B.; Sraer, J.D.; Friedlander, G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ. Res., 1998, 83, 683.
74. Funakoshi, Y.; Ichiki, T.; Shimokawa, H.; Egashira, K.; Takeda, K.; Kaibuchi, K.; Takeya, M.; Yoshimura, T.; Takeshita, A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension, 2001, 38, 100.
75. Takeda, K.; Ichiki, T.; Tokunou, T.; Iino, N.; Fujii, S.; Kitabatake, A.; Shimokawa, H.; Takeshita, A. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb. Vasc. Biol., 2001, 21, 868.
76. Hajra, L.; Evans, A.I.; Chen, M.; Hyduk, S.J.; Collins, T.; Cybulsky, M.I. The NF--B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc. Natl. Acad. Sci. USA, 2000, 97, 9052.
77. Bar-Sagi, D.; Hall, A. Ras and Rho GTPases: a family reunion. Cell, 2000, 103, 227.
78. Bishop, A. L.; Hall, A. Rho GTPases and their effector proteins. Biochem. J., 2000, 348, 241.
79. Montaner, S.; Perona, R.; Saniger, L.; Lacal, J. C. Multiple signalling pathways lead to the activation of the nuclear factor -B by the Rho family of GTPases. J. Biol. Chem., 1998, 273, 12779.
80. Perona, R.; Montaner, S.; Saniger, L.; Sanchez-Perez, I.; Bravo, R.; Lacal, J. C. Activation of the nuclear factor--B by Rho, CDC42, and Rac-1 proteins. Genes Dev., 1997, 11, 463.
81. Wang, H. W.; Liu, P.Y.; Oyama, N.; Rikitake, Y.; Kitamoto, S.; Gitlin, J.; Liao, J.K.; Boisvert, W. A. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J., 2008, 22(10), 3561.
82. Morishige, K.; Shimokawa, H.; Eto, Y.; Kandabashi, T.; Miyata, K.; Matsumoto, Y.; Hoshijima, M.; Kaibuchi, K.; Takeshita, A. Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb. Vasc. Biol., 2001, 21(4), 548.
83. Honing, H., van den Berg, T.K.; van der Pol, S.M.; Dijkstra, C.D.; van der Kammen, R.A.; Collard, J.G.; de Vries, H.E. RhoA activation promotes transendothelial migration of monocytes via ROCK. J. Leukoc. Biol., 2004, 75, 523.
84. Ni, W.; Egashira, K.; Kataoka, C.; Kitamoto, S.; Koyanagi, M.; Inoue, S.; Takeshita, A. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res., 2001, 89(5), 415.
85. Taylor, A.J.; Kent, S.M.; Flaherty, P.J.; Coyle, L.C.; Markwood, T.T.; Vernalis, M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intimal medial thickness. Circulation, 2002, 106, 2055.
86. Crouse, J.R., III.; Byington, R.P.; Bond, M.G.; Espeland, M.A.; Craven, T.E.; Sprinkle, J.W.; McGovern, M.E.; Furberg, C.D. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol., 1995, 75, 455.
87. Nissen, S.E.; Tuzcu, E.M.; Schoenhagen, P.; Brown, B.G.; Ganz, P.; Vogel, R.A.; Crowe, T.; Howard, G.; Cooper, C.J.; Brodie, B.; Grines, C.L.; DeMaria, A.N.; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004, 291, 1071.
88. Archipoff, G.; Beretz A.; Freyssinet J.M.; Klein-Soyer, C.; Brisson, C.; Cazenave, J.P. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumor necrosis factor, thrombin or phorbol ester. Biochem. J., 1991, 273, 679.
89. Eto, M.; Kozai, T.; Cosentino, F.; Joch, H.; Lüscher, T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation, 2002, 105(15), 1756.
90. Liu, P.Y.; Liu, Y.W.; Lin, L.J.; Chen, J.H.; Liao, J.K. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation, 2009, 119(1), 131.
91. Maseri, A.; Severi, S.; Nes, M.D.; L'Abbate, A.; Chierchia, S.; Marzilli, M.; Ballestra, A.M.; Parodi, O.; Biagini, A.; Distante, A. "Variant" angina: one aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence and clinical and coronary arteriographic findings in 138 patients. Am. J. Cardiol., 1978, 42, 1019.
92. Yasue, H.; Kugiyama, K. Coronary spasm: clinical features and pathogenesis. Intern. Med., 1997, 36, 760.
93. Yasue, H.; Omote, S.; Takizawa, A.; Nagao, M. Coronary arterial spasm in ischemic heart disease and its pathogenesis. A review. Circ. Res., 1983, 52(Suppl. I), 147-59.
94. Maseri, A.; L'Abbate, A.; Baroldi, G.; Chierchia, S.; Marzilli, M.; Ballestra, A.M. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of "preinfarction" angina. N. Engl. J. Med., 1978, 299, 1271.
95. Nakamura, M.; Takeshita, A.; Nose, Y. Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. Circulation, 1987, 75, 1110.
96. Uehata, M.; Ishizaki, T.; Satoh, H.; Ono T.; Kawahara, T.; Morishita, T.; Tamakawa, H.; Yamagami, K.; Inui, J.; Maekawa, M.; Narumiya, S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature, 1997, 389, 990.
97. Okumura, K.; Osanai, T.; Kosugi, T.; Hanada, H.; Ishizaka, H.; Fukushi, T.; Kamada, T.; Miura, T.; Hatayama, T.; Nakano, T.; Fujino, Y.; Homma, Y. Enhanced phospholipase C activity in the cultured skin fibroblast obtained from patients with coronary spastic angina: possible role for enhanced vasoconstrictor response. J. Am. Coll. Cardiol., 2000, 36, 1847.
98. Nakano, T.; Osanai, T.; Tomita, H.; Sekimata, M.; Homma, Y.; Okumura, K. Enhanced activity of variant phospholipase Cdelta1 protein (R257H) detected in patients with coronaryartery spasm. Circulation, 2002, 105, 2024.
99. Shimokawa, H. Cellular and molecular mechanisms of coronary artery spasm-lessons form animal models. Jpn. Circ. J., 2000, 64, 1.
100. Kandabashi, T.; Shimokawa, H.; Mukai, Y.; Matoba, T.; Kunihiro, I.; Morikawa, K.; Ito, M.; Takahashi, S.; Kaibuchi, K.; Takeshita, A. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler. Thromb. Vasc. Biol., 2002, 22(2), 243.
101. Ming, X.F.; Viswambharan, H.; Barandier, C.; Ruffieux, J.; Kaibuchi, K.; Rusconi, S.; Yang, Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell Biol., 2002, 22, 8467.
102. Morikami, Y.; Ogawa, H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early coronary atherosclerosis. Circulation, 1990, 81, 482.
103. Wolfrum, S.; Grimm, M.; Heidbreder, M.; Dendorfer, A.; Katus, H.A.; Liao, J.K.; Richardt, G. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme a reductase inhibitor is mediated by endothelial nitric oxide synthase. J. Cardiovasc. Pharmacol., 2003, 41, 474.
104. Sawada, N.; Itoh, H.; Ueyama, K.; Yamashita, J.; Doi, K.; Chun, T.H.; Inoue, M.; Masatsugu, K.; Saito, T.; Fukunaga, Y.; Sakaguchi, S.; Arai, H.; Ohno, N.; Komeda, M.; Nakao, K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation, 2000, 101, 2030.
105. Sato, S.; Ikegaki, I.; Asano, T.; Shimokawa, H. Antiischemic properties of fasudil in experimental models of vasospastic angina. Jpn. J. Pharmacol., 2001, 87(1), 34.
106. Sato, M.; Tani, E.; Fujikawa, H.; Kaibuchi, K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ. Res., 2000, 87, 195.
107. Mizuno Y.; Yasue H.; Harada E.; Itoh T.; Nakayama M.; Yoshimura M. Effects of statins on coronary artery spasm using quantitative coronary analysis. Circulation, 2007, 116(Suppl. II), 562.
108. Inokuchi, K.; Ito, A.; Fukumoto, Y.; Matoba, T.; Shiose, A.; Nishida, T.; Masuda, M.; Morita, S.; Shimokawa, H. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J. Cardiovasc. Pharmacol., 2004, 44(3), 275.
109. Otsuka, T.; Ibuki, C.; Suzuki, T.; Ishii, K.; Kodani, E.; Atarashi, H.; Kishida, H.; Takano, T. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. Circ. J., 2006, 70(4), 402.
110. Otsuka, T.; Ibuki, C.; Suzuki, T.; Ishii, K.; Yoshida, H.; Kodani, E.; Kusama, Y.; Atarashi, H.; Kishida, H.; Takano, T.; Mizuno, K. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron. Artery. Dis., 2008, 19(2), 105.
111. Zhao, Z.Q.; Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc. Res., 2002, 55(3), 438.
112. Hamid, S.A.; Bower, H.S.; Baxter, G.F. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(6), H2598.
113. Bao, W.; Hu, E.; Tao, L.; Boyce, R.; Mirabile, R.; Thudium, D.T.; Ma, X.L.; Willette, R.N.; Yue, T.L. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc. Res., 2004, 61(3), 548.
114. Ikeda, F.; Terajima, H.; Shimahara, Y.; Kondo, T.; Yamaoka, Y. Reduction of hepatic ischemia/reperfusion-induced injury by a specific ROCK/Rho kinase inhibitor Y-27632. J. Surg. Res., 2003, 109(2), 155.
115. Takeda, K.; Jin, M.B.; Fujita, M.; Fukai, M.; Sakurai, T.; Nakayama, M.; Taniguchi, M.; Suzuki, T.; Shimamura, T.; Furukawa, H.; Todo, S. A novel inhibitor of Rho-associated protein kinase, Y-27632, ameliorates hepatic ischemia and reperfusion injury in rats. Surgery, 2003, 133(2), 197.
116. Teraishi, K.; Kurata, H.; Nakajima, A.; Takaoka, M.; Matsumura, Y. Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats. Eur. J. Pharmacol., 2004, 505(1-3), 205.